Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are novel oral hypoglycemic agents garnering much attention for their substantial benefits. These recent data have positioned SGLT2i at the forefront of diabetic chronic kidney disease (CKD) and heart failure management. SGLT2i use post-kidney trans...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramakrishnan, Pavithra, Garg, Neetika, Pabich, Samantha, Mandelbrot, Didier A, Swanson, Kurtis J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514750/
https://www.ncbi.nlm.nih.gov/pubmed/37746038
http://dx.doi.org/10.5500/wjt.v13.i5.239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514750/
https://www.ncbi.nlm.nih.gov/pubmed/37746038
http://dx.doi.org/10.5500/wjt.v13.i5.239

Ejemplares similares